227 AP and >100 CDx engagements

Transcription

1 Anatomic pathology Q 2 Solutions comprehensive in-house end-to-end anatomic pathology and adjunct molecular services are designed to meet your clinical trial needs. Anatomic pathology is a vital part of the study and treatment of disease. The future of anatomic pathology testing across the market landscape is quickly changing, and you need a partner who can deliver the services you need. Having a comprehensive anatomic pathology strategy can be crucial to ensuring clinical and commercial success of your product. Q 2 Solutions helps biopharma and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q 2 Solutions delivers on this promise by offering tailored anatomic pathology solutions, by providing delivery excellence, and by bringing together our knowledge and expertise to help you make better decisions and shape better outcomes.

2 Tailored anatomic pathology solutions With access to commercial clinical laboratories and a full in-house global Anatomic Pathology (AP) service with a footprint in the Americas, Europe, Asia-Pac and China, including more than 25 expert pathologists, and a lab operations team who are adept at assay transfer and validation, we have the ability to support your unique study needs. We create tailored solutions for every trial, based on tissue and tumor type, staining requirements, and the need for customized assays. Our capabilities include: Co-localized central laboratories with AP and tissue-based molecular testing Centralized study set-up with flexible database configuration Tissue sample accessioning and processing Licensed histo-technologists Digital and remote pathology services Redundant labs for business continuity and management of peak volumes Companion diagnostics experience and solid relationships with several manufacturers Access to oncology, pathology, technology experts Access to commercial clinical laboratories Certified pathologists covering a broad range of specialties, who can provide scientific oversight as principal investigator for your companion diagnostics study Robust process for Path Report Form (PRF) entry and result reporting Our co-localized AP-molecular testing laboratories employ quality management systems that ensure consistency and specimen integrity from sample collection, preparation and analysis to results reporting. Expert in-house pathologists specialized in histopathology and cytopathology, with sub-specialization in hematopathology, GI pathology, dermatopathology and other areas, with >20 years experience have the expertise to help guide your project successfully through regulatory submission. Capitalize on our ability to validate new assays across a fullspectrum of technologies, including experience in the fields of immunohistochemistry (IHC) and in-situ hybridization (FISH, CISH, DISH). Companion diagnostics experience Our scientific experts provide you with an optimal path to co-develop your companion diagnostic with clinical development of the therapeutic, regulatory submission and market launch. Our integrated approach is designed so you optimize time to market and commercial success. Real world anatomic pathology and companion diagnostics experience providing solutions to our customers across the globe including: 227 AP and >100 CDx engagements With Q 2 Solutions comprehensive solution for companion diagnostics development, we can take your therapeutic in tandem with the companion diagnostic to market faster. Our integrated solution provides flexible support across the development spectrum, from biomarker R&D services, assay development and optimization, to global execution, regulatory support, and commercial, diagnostics and late-phase expertise. Companion diagnostics development partner of choice Extensive expertise to accelerate your tandem development pathway Commercial diagnostic & market analytics capabilities IVD Registration & market access expertise (510(k); PMA; CE Mark) LDT Biomarker selection & study design, informatics/analytics Assay development, validation & scale up Strategic consulting: regulatory & reimbursement, enrollment solutions Deep experience in 3-4 way CDx development relationships Global clinical trial wraparound services including Central Lab Access to reagent kit production / GMP Pre-launch medical communications & proficiency training Rx Preclinical Clinical development FDA filing Launch IVD Feasibility Development Lab validation Clinical validation IVD Registration Commercialization & modification

3 Q 2 Solutions has helped develop of all FDA-approved breakthrough/ 40% first-in-class drugs since 2011 >25 expert pathologists Q 2 Solutions has helped develop of all FDA-approved precision 67% medicine drugs of 2016 Through biomarker selection, assay design and development, clinical validation, regulatory and commercial phases, we have a centralized lab network, deep domain expertise and relationships with IVD companies which allow us to co-develop and commercialize drugs with complex diagnostics paradigms. Anatomic pathology and companion diagnostics Co-development and commercialization of drugs with complex diagnostic paradigms Tumor environment Tumor morphology Tumor percentage Heterogeneity Protein expression IHC Leukocyte infiltration Immunoscore Clinical pathology challenge Clinical pathology solution Cytogenetics Amplification Translocation Fusion/deletion Tissue limitation Turnaround time Multiplex assays Automated platforms Digital pathology Cancer patients Genomics/genetics Mutation analysis Exomics mrna Candidate patient for targeted therapy Interpretation Multi-disciplinary pathologist training Expertise to help guide decisions across the development continuum Gene signature Cell of origin Disease subtype Inflammatory milieu Innovation Promoting faster, more collaborative analysis through the use of innovative, leading edge products and services to enable communication of richer efficacy signals faster and more cost-effectively. Innovative technology: Incorporation of image analysis validation in addition to remote pathology (telepathology) services are integral for quality review and proficiency testing and analysis. Automation in FISH: BioView allows for automated scanning for scoring and archiving images that improves productivity, accuracy, and reproducibility compared to manual scoring. This eliminates double data entry, which increases the efficacy of our labs. Additionally, by performing a combined IHC and FISH analysis, the number of samples needed from the patient is reduced. Digital pathology solutions: Aperio Scansope ensures quality, speed, and reliability for your sample analysis. Our expert internal and external pathologists are given remote access providing second reviews and opinions in a centralized read. This results in a faster turnaround time and enables an image repository for biostatistical analysis. Supported >130 phase 1-3 clinical trials for scanning of H&E and IHC slides

4 Anatomic pathology and molecular testing services We showcase a full spectrum of comprehensive in-house end-to-end anatomic pathology and molecular testing services to meet today s drug development needs, including: Anatomic pathology services Molecular services Tissue processing (FFPE) TMA construction H&E / special stains Gynecological/FNA/non-gyn cytology Hematopathology Immunohistochemistry (IHC) In-situ hybridization (FISH, CISH, DISH) Full slide aperio imaging and slide scanning Remote pathology (telepathology) and image repository Sample biorepository options Companion diagnostics capabilities DNA/RNA extraction/purification qpcr/rt-pcr open system qpcr/rt-pcr closed system Sanger Sequencing Next Generation Sequencing Pyro Sequencing RNA Sequencing Illumina Array-based genotyping PCR-based gene expression analysis Array-based gene expression analysis Nanostring gene expression analysis HTG Mutation, gene defect & expression analysis Circulating Free DNA (cfdna) mutation analysis Circulating Tumor Cell (CTC) analysis These services are led by our chief pathologist who has >22 years anatomic and clinical pathology experience. Our chief pathologist also manages global quality and harmonization of AP, IHC, ISH (FISH, CISH, DISH) testing and reporting in Q 2 Solutions labs, and oversees AP assay validation and global pathologist training and proficiency training of staff. Delivery excellence We offer a quality management system that delivers high quality, dependable data for your study. All clinical laboratories across our regions ensure a globally harmonized SOP process that minimizes technical variability in your study. All of our expert pathologists, histotechnologists, clinical and laboratory staff are trained in good documentation practices, with each anatomic pathology lab containing on-site pathologists with >20 years experience. Metrics are captured for turnaround time in each of our labs, with a goal of at least 98% achievement of turnaround time for each study. Backed by the scientific expertise of our in-house pathologists, our AP laboratories also participate in an accuracy-driven external quality assurance program (CAP Proficiency Testing) that supports our goal of achieving global harmonization, standardization and high quality results across the globe for every study. Q2 Solutions global footprint Anatomic pathology capabilities across the globe providing rapid testing, harmonized data, and optimized logistics costs. Edinburgh, UK Valencia, CA San Juan Capistrano, CA Teterboro, NJ RTP, NC Atlanta, GA Beijing, China Singapore Translational Science Lab AP labs Molecular / Genetics Central Lab, AP, Assay Development, Molecular / Genetics *Supporting more than 180,000 investigative sites worldwide

5 Spotlight on Oncology With experience in anatomic and molecular pathology, flow cytometry, immunoassay and genomics-based assay development and testing, Q 2 Solutions can provide customized, global laboratory solutions specifically suited for the unique combinations of therapeutic indication and targeted mechanismof-action driving modern oncology drug development. Oncology molecular testing innovation Industry trends Testing solutions Less invasive sampling Liquid biopsy: cell free nucleic acids and circulating tumor cells (CTCs) Mutation detection including Next Generation Sequencing Flow cytometry, immunoassays, proteomics Shift toward molecular methods Next generation sequencing (NGS) replacing FISH panels Gene expression panels replacing multiple IHCs Ultra-high sensitivity Mutation detection at 0.01% Single-cell analysis by flow cytometry/molecular platforms Detection of disease and early resistance Companion diagnostics Already established for many methods Expanding to genomics/ngs platforms We offer leading-edge solutions to meet the toughest drug development challenges: Trend in the industry to systematically include cfdna for oncology trials We provide CTC enumeration and characterization and cfdna to generate valuable information in clinical studies We offer NGS to lead oncology services Immuno-oncology Experience predicting and assessing a patient s response to checkpoint inhibitors is an integral function in anatomic pathology (AP) as it relates to immuno-oncology drug development. Once a tissue sample is received, central AP testing is performed and data can be mined for immune-oncology characterizations, such as PD-L1 proteins or tumor-infiltrating lymphocytes. We then take those characterizations and apply them to drug studies, such as the creation of predictive biomarkers for patient selection. We conduct T-cell receptor and B-cell receptor repertoire analysis We combine anatomic pathology with cutting-edge molecular testing platforms: HTG, Nanostring, NGS Oncology and hematology make up almost 1/3 lab of anatomic pathology work Q 2 Solutions has helped develop of all FDA-approved oncology 61% pharmacogenomics products to date Q 2 Solutions has helped develop of all FDA-approved oncology 54% precision medicine drugs since 2014

6 Shaping outcomes Q 2 Solutions has the breadth and depth of scientific experience and expertise across all major therapeutic areas to give drug developers a competitive advantage helping ensure your success in clinical trials, regulatory approvals and new product launches. >3,300 laboratory studies conducted since 2011 Oncology & Hematology Other conditions Immuno & Infectious Diseases Endocrine & Metabolic Disorders Pulmonary Central Nervous System Arthritis Cardiovascular Psychiatric Disorders GI Dermatolological G. Urinary & OB/GYN 0 5% 10% 15% 20% 25% 30% We re able to go a step further with our capability to validate, transfer and employ new assays to meet today s development opportunities. These abilities add significant value as we develop new assays for your trials Immunoassays Flow cytometry LCMS/MS >400 assays validated in 2015 Validated >30 assays to the field of IHC-FISH-ISH Q 2 Solutions is your partner of choice for any development program that requires anatomic pathology services because we re able to go a step further to help you understand how these capabilities can help deliver actionable medical insights for better health Molecular APC (IHC-FISH-ISH) Vaccines Genomics (EA) ADME BioA Immunogenicity Clinical safety Contact us Toll free: Direct: International: +44 (0) Website: Copyright 2017 Q 2 Solutions. All rights reserved. Q Jul2017